×
About 143 results

ALLMedicine™ Vasculitic Neuropathy Center

Research & Reviews  46 results

Role of complement components in vasculitic neuropathy associated with systemic lupus e...
https://doi.org/10.1002/mus.27636
Muscle & Nerve; Fukami Y, Koike H et. al.

May 19th, 2022 - The mechanism of complement-mediated neurological injury in vasculitic neuropathy associated with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) is unknown. The current study aimed to investigate the local activation of the compl...

Analgesic Effect of rTMS in Vasculitic Neuropathy
https://clinicaltrials.gov/ct2/show/NCT04720196

Mar 8th, 2022 - Vasculitic neuropathies (VN) are a group of disorders resulting from inflammation of predominantly small vessels with destruction of their walls and subsequent ischemic damage of peripheral nerves. Neural damage may or may not coexist with the dam...

Adalimumab-induced sensory vasculitic neuropathy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768498
BMJ Case Reports; Sim NK, Ismail A et. al.

Jan 19th, 2022 - Vasculitis and other autoimmune conditions are known complications of tumour necrosis factor alpha (TNF-α) inhibitor use. By definition, TNF-α inhibitor induced vasculitis is a secondary systemic vasculitis. However, its phenotype is varied and ca...

Evolution of Neuropathies Associated With Necrotizing Vasculitis
https://clinicaltrials.gov/ct2/show/NCT05164822

Dec 21st, 2021 - Necrotizing Vasculitis are inflammatory diseases of the wall of vessels. Neurological damage of the peripheral nerve varies from 7% to 50% of cases depending on the type of Necrotizing Vasculitis. Peripheral neurological impairment is rarely life ...

Combination rituximab and intravenous immunoglobulin for treatment of refractory vascul...
https://doi.org/10.1093/rheumatology/keab069
Rheumatology (Oxford, England); Lima K, Tavee J et. al.

Jan 28th, 2021 - Limited evidence exists to guide treatment of refractory vasculitic neuropathy. While rituximab (RTX) and IVIG have both been proposed as individual treatment options for these patients, combination therapy has never been reported. Written informe...

see more →

Clinicaltrials.gov  3 results

Analgesic Effect of rTMS in Vasculitic Neuropathy
https://clinicaltrials.gov/ct2/show/NCT04720196

Mar 8th, 2022 - Vasculitic neuropathies (VN) are a group of disorders resulting from inflammation of predominantly small vessels with destruction of their walls and subsequent ischemic damage of peripheral nerves. Neural damage may or may not coexist with the dam...

Evolution of Neuropathies Associated With Necrotizing Vasculitis
https://clinicaltrials.gov/ct2/show/NCT05164822

Dec 21st, 2021 - Necrotizing Vasculitis are inflammatory diseases of the wall of vessels. Neurological damage of the peripheral nerve varies from 7% to 50% of cases depending on the type of Necrotizing Vasculitis. Peripheral neurological impairment is rarely life ...

Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication
https://clinicaltrials.gov/ct2/show/NCT00188201

Nov 29th, 2005 - The current proposal addresses the hypothesis that neurocognitive and neurochemical abnormalities may occur in individuals with HCV-infection who do not have liver cirrhosis or vasculitic neuropathy, and that this phenomenon may result from a dire...

see more →

News  8 results

Pembrolizumab and Nivolumab May Cause Neurologic Events
https://www.mdedge.com/neurology/article/146946/neuro-oncology/pembrolizumab-and-nivolumab-may-cause-neurologic-events

Sep 12th, 2017 - Approximately 3% of patients developed adverse neurologic events within 12 months of receiving nivolumab or pembrolizumab, according to the results of a single-center retrospective study published online ahead of print September 5 in JAMA Neurolog.

Pembrolizumab, nivolumab linked to 3% rate of neurologic events
https://www.mdedge.com/internalmedicine/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
Amy Karon

Sep 5th, 2017 - Three percent of patients developed immune-related adverse neurologic events within 12 months of receiving nivolumab or pembrolizumab, according to the results of a single-center retrospective study. These syndromes included myopathy, axonal thora.

Fast Five Quiz: Do You Know the Zika Virus Guidelines?
https://reference.medscape.com/viewarticle/857714_2

Jan 27th, 2016 - Answer 1/5 Which of the following has been associated with Zika virus infection? Your peers chose: Guillain-Barré syndrome 0% Vasculitic neuropathy 0% Myasthenia gravis 0% Cauda equina syndrome 0% Guillain-Barré syndrome has been associated with Z...

IVIg for Sjogren's Neuropathy: Worth the Price?
https://www.medscape.com/viewarticle/777596

Jan 17th, 2013 - Experience of Intravenous Immunoglobulin Therapy in Neuropathy Associated With Primary Sjögren's Syndrome: A National, Multicentric Retrospective Study Rist S, Sellam J, Hachulla E, et al Arthritis Care Res (Hoboken). 2011;63:1339-1344 Study Summa...

IVIg for Sjogren's Neuropathy: Worth the Price?
https://www.medscape.com/viewarticle/777596_1

Jan 17th, 2013 - Experience of Intravenous Immunoglobulin Therapy in Neuropathy Associated With Primary Sjögren's Syndrome: A National, Multicentric Retrospective Study Rist S, Sellam J, Hachulla E, et al Arthritis Care Res (Hoboken). 2011;63:1339-1344 Study Summa...

see more →